Cohort of HIV-infected patients who began treatment with protease inhibitor in 1997-1999. Follow-up over 4 years on the long-term effects linked with adherence and tolerance (COPILOT). FRESH-PEF60024-en Catherine LEPORT Cohort of HIV-infected patients who began treatment with protease inhibitor in 1997-1999. Follow-up over 4 years on the long-term effects linked with adherence and tolerance (COPILOT). ANRS CO8 APROCO-COPILOTE FRESH-PEF60024-en 60024 FRESH-PEF60024 Catherine LEPORT AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) Epidemiology France Portal (PEF) AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) ABBOTT FRANCE BOEHRINGER INGELHEIM INTERNATIONAL GMBH BRISTOL MYERS SQUIBB PHARMA FRANCE S.A COLLEGE DES UNIVERSITAIRES DE MALADIES INFECTIEUSES ET TROPICALES (CMIT) F. HOFFMANN-LA ROCHE AG GILEAD SCIENCES GLAXOSMITHKLINE (FRANCE) PFIZER (FRANCE) SIDACTION (ECS) null unexpected events Observed health events serious adverse events cardiovascular risk factors Infectious disease medicine Biological determinants: Genetic predisposition Healthcare system determinants: Use of care Biological determinants Healthcare system determinants General objective: To investigate determinants for long-term effects of adherence and tolerance to highly active antiretroviral drugs, in relation to patients infected with HIV-1 who were treated for the first time under a protease inhibitor in 1997-99. Secondary objectives: - to determine the part that host genetic polymorphisms play in the progression of the infection and onset of serious adverse events - to investigate viral load and antiretroviral resistance in plasma cell compartments in relation to antiretroviral concentrations over time. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Patients included in the APROCO cohort (adults infected with HIV-1 at first prescription of protease inhibitor in 1997-99), monitored for four years in APROCO after initial enrolment, monitored by voluntary services in order to participate in extended follow-up, having given their written consent. Clinical data Participant-reported health data Biological data Paraclinical data (non-biological) : Anthropometry Health event/morbidity Health event/mortality Quality of life/health perception Other Through organizations (health services or institutions schools businesses etc.) [1000-10000[ individuals Self-administered questionnaire Interview with the participant (including clinical) Observational Study Observational Study Cohort study 717: Copilote 1281: Aproco Unknown Restricted access Data may be used by academic teams Data may not be used by industrial teams Access on specific project only